Baili Tianheng (688506.SH): Yizekang combined with radiotherapy for the treatment of locally advanced unresectable head and neck squamous cell carcinoma and other solid tumors receives drug clinical trial approval

Zhitong Finance APP News, Baili Tianheng (688506.SH) announced that the company recently received the "Drug Clinical Trial Approval Notice" officially approved and issued by the National Medical Products Administration (NMPA). The clinical trial of the combination therapy of the company's independently developed globally first-in-class, new-concept, and globally first and only approved for marketing EGFRHER3 bispecific antibody-drug conjugate Yizekang (lunkanilongtumab, BL-B01D1/iza-bren) has been approved.